Multiple Sclerosis

Featured Article
The National Multiple Sclerosis Society has issued recommendations for the use of the COVID-19 vaccine among patients with multiple sclerosis.
In a new study published in Multiple Sclerosis Journal, researchers investigated potential cerebrospinal fluid markers for long-term disability among patients with relapsing multiple sclerosis.
In multiple sclerosis (MS), cognitive management often consists of pharmacologic and nonpharmacologic interventions. In your experience, which nonpharmacologic interventions have been most helpful to your patients with MS?
True or False: Guidelines from the American Academy of Neurology state that health care practitioners should offer disease-modifying therapies (DMTs) to patients with relapsing forms of multiple sclerosis who have had recent clinical relapses or magnetic resonance imaging (MRI) activity. Test your knowledge in our pop quiz!
Individuals can develop multiple sclerosis (MS) at any age, but during which age range does MS most commonly occur? Test your knowledge in our pop quiz.
True or False: Current guidelines recommend magnetic resonance imaging (MRI) of the brain with gadolinium to diagnose multiple sclerosis.
In an analysis of the SUNBEAM and DAYBREAK studies, researchers aimed to compare the effects of ozanimod and intramuscular interferon on Symbol Digit Modalities Test scores among patients aged 18 to 55 years with relapsing multiple sclerosis.
Because no consensus currently exists for when and how aggressively to treat relapsing-remitting multiple sclerosis (RRMS), researchers compared the effects of early intensive treatment vs moderate-efficacy treatment followed by escalation among patients with RRMS. The findings were presented at MSVirtual2020.
Rituximab (RTX), an anti-CD20 monoclonal antibody, is commonly used as an off-label treatment for multiple sclerosis (MS). In a new study presented at MSVirtual2020, researchers compared the safety and efficacy of RTX at low and high doses among patients with MS.
A drug that was first approved in 2009 for the treatment of chronic lymphocytic leukemia has now been approved by the FDA to treat relapsing forms of multiple sclerosis.
Multiple sclerosis has been described for centuries, though physicians at the time did not have a name for the condition. In what year was multiple sclerosis officially recognized in the United States?